Herpes zoster infection after rituximab induction therapy in patient with myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis: a case report

Ho Hsiang Chang; Hsuan Chen; Wei Hung Lin

doi:10.1093/omcr/omac134

Herpes zoster infection after rituximab induction therapy in patient with myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis: a case report

Ho Hsiang Chang, Hsuan Chen, Wei Hung Lin

Department of Internal Medicine(NCKUH)

Research output: Contribution to journal › Article › peer-review

Abstract

Induction treatment with rituximab—an anti-CD20 monoclonal antibody—may increase the risk of varicella-zoster virus (VZV) reactivation in patients with antineutrophil-cytoplasmic-antibody-associated vasculitis (AAV). Our case report shows VZV reactivation following rituximab treatment in AAV patients. The recombinant zoster vaccine should be recommended before the start of induction treatment with rituximab.

Original language	English
Pages (from-to)	417-419
Number of pages	3
Journal	Oxford Medical Case Reports
Volume	2022
Issue number	12
DOIs	https://doi.org/10.1093/omcr/omac134
Publication status	Published - 2022 Dec 1

All Science Journal Classification (ASJC) codes

Parasitology
Microbiology
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/omcr/omac134

Cite this

@article{9173158dc0af4a7ca1a4bf807b15ce23,

title = "Herpes zoster infection after rituximab induction therapy in patient with myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis: a case report",

abstract = "Induction treatment with rituximab—an anti-CD20 monoclonal antibody—may increase the risk of varicella-zoster virus (VZV) reactivation in patients with antineutrophil-cytoplasmic-antibody-associated vasculitis (AAV). Our case report shows VZV reactivation following rituximab treatment in AAV patients. The recombinant zoster vaccine should be recommended before the start of induction treatment with rituximab.",

author = "Chang, {Ho Hsiang} and Hsuan Chen and Lin, {Wei Hung}",

note = "Funding Information: I would like to express my appreciation to Dr Wei-Hung Lin for his valuable suggestions during the development of this research and for comments that greatly improved the manuscript. Publisher Copyright: {\textcopyright} The Author(s) 2022. Published by Oxford University Press. All rights reserved.",

year = "2022",

month = dec,

day = "1",

doi = "10.1093/omcr/omac134",

language = "English",

volume = "2022",

pages = "417--419",

journal = "Oxford Medical Case Reports",

issn = "2053-8855",

publisher = "Oxford University Press",

number = "12",

}

TY - JOUR

T1 - Herpes zoster infection after rituximab induction therapy in patient with myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis

T2 - a case report

AU - Chang, Ho Hsiang

AU - Chen, Hsuan

AU - Lin, Wei Hung

N1 - Funding Information: I would like to express my appreciation to Dr Wei-Hung Lin for his valuable suggestions during the development of this research and for comments that greatly improved the manuscript. Publisher Copyright: © The Author(s) 2022. Published by Oxford University Press. All rights reserved.

PY - 2022/12/1

Y1 - 2022/12/1

N2 - Induction treatment with rituximab—an anti-CD20 monoclonal antibody—may increase the risk of varicella-zoster virus (VZV) reactivation in patients with antineutrophil-cytoplasmic-antibody-associated vasculitis (AAV). Our case report shows VZV reactivation following rituximab treatment in AAV patients. The recombinant zoster vaccine should be recommended before the start of induction treatment with rituximab.

AB - Induction treatment with rituximab—an anti-CD20 monoclonal antibody—may increase the risk of varicella-zoster virus (VZV) reactivation in patients with antineutrophil-cytoplasmic-antibody-associated vasculitis (AAV). Our case report shows VZV reactivation following rituximab treatment in AAV patients. The recombinant zoster vaccine should be recommended before the start of induction treatment with rituximab.

UR - http://www.scopus.com/inward/record.url?scp=85159361043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85159361043&partnerID=8YFLogxK

U2 - 10.1093/omcr/omac134

DO - 10.1093/omcr/omac134

M3 - Article

AN - SCOPUS:85159361043

SN - 2053-8855

VL - 2022

SP - 417

EP - 419

JO - Oxford Medical Case Reports

JF - Oxford Medical Case Reports

IS - 12

ER -

Herpes zoster infection after rituximab induction therapy in patient with myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis: a case report

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this